The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, August 2016
|
| DOI | 10.2147/ndt.s104020 |
| Pubmed ID | |
| Authors |
Weihong Kuang, Liantian Tian, Lili Yue, Jin Li |
| Abstract |
The objective of this study was to investigate the therapeutic effects of escitalopram in conjunction with Jiuweizhenxin-keli on neuroelectrophysiology in patients with major depressive disorders (MDD). Patients with depressive episode of MDD according to the criteria of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were randomly assigned to Esc group (30 patients) receiving escitalopram treatment and JK group (30 patients) treated with a combination of escitalopram and Jiuweizhenxin-keli. The healthy control (HC) group (30 persons with normal health condition) served as control. All groups were subject to examination of 24-item Hamilton Depression Rating Scale and Hamilton Anxiety Scale, mismatch negativity (MMN), and sensory gating potential P50 (SG-P50) of event-related potentials. Data were collected at three different time points: baseline (before treatment) and week 2 and week 6 post treatment. At baseline, all electrophysiological parameters of patients with MDD were significantly higher than those of HCs. After treatment, in the Esc group, MMN latency, S2-P50 amplitude, and S2-P50/S1-P50 amplitude ratio decreased; however, the decrements were not statistically significant compared to either baseline or the HC group. Also, no significant changes were observed in the percentage of individuals whose S2-P50/S1-P50 ≥0.5 in the Esc group. On the other hand, in the JK group after a 6-week treatment, MMN latency (206.35±32.14 ms) was significantly shorter than that of the Esc group (219.57±36.51 ms), S2-P50 amplitude (7.27±4.85 μV) reduced significantly compared with the baseline level (10.21±4.10 μV), the percentage of individuals whose S2-P50/S1-P50 ≥0.5 in the JK group greatly decreased and this was not significantly different compared to that of the HC group (P≥0.05). Neuroplasticity of patients with MDD is apparently disturbed, characterized by aberrant MMN latency and SG-P50-related event-related potential parameters. A combination of escitalopram and Jiuweizhenxin-keli treatment can markedly restore these neuroelectrophysiological features, and thus, could be a novel therapeutic solution for improving the impaired neuroplasticity of MDD patients. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 29% |
| Other | 2 | 12% |
| Student > Master | 2 | 12% |
| Student > Bachelor | 2 | 12% |
| Student > Doctoral Student | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 5 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
| Nursing and Health Professions | 1 | 6% |
| Business, Management and Accounting | 1 | 6% |
| Psychology | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 5 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 August 2016.
All research outputs
#17,286,379
of 25,374,647 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,901
of 3,132 outputs
Outputs of similar age
#252,533
of 381,036 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#75
of 102 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 381,036 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 102 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.